AGRYLIN (anagrelide HCl)
THROMBOCYTOSIS AGENTS · THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE ·+1
SHIRE US INC.
Drug class
Thrombocytosis Agents
"Thrombocytosis agents" is an informal grouping rather than a distinct, standardized pharmacological class in major regulatory classifications such as the FDA Established Pharmacologic Class system. Read more about Thrombocytosis Agents
4 drugs in this class 4 manufacturers
Drugs in Thrombocytosis Agents
ANAGRELIDE HCL
THROMBOCYTOSIS AGENTS · THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE ·+1
TORRENT PHARMAC
ANAGRELIDE HCL
THROMBOCYTOSIS AGENTS · THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE ·+1
CHARTWELL RX LL
ANAGRELIDE HCL
THROMBOCYTOSIS AGENTS · THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE ·+1
ANI PHARMACEUTI
Filter & compare in the drug finder →
Opens the drug finder with Thrombocytosis Agents preselected. Add indication or manufacturer filters there.
"Thrombocytosis agents" is an informal grouping rather than a distinct, standardized pharmacological class in major regulatory classifications such as the FDA Established Pharmacologic Class system.
In clinical practice and reference databases, this term generally refers to platelet-lowering or cytoreductive agents used to reduce pathologically elevated platelet counts.
These therapies—most notably anagrelide, hydroxyurea, and interferon formulations—work by selectively inhibiting megakaryocyte maturation or exerting broader antineoplastic and antiproliferative effects in the bone marrow to curb excessive platelet production.
Their primary therapeutic role is in hematology for myeloproliferative neoplasms, most prominently essential thrombocythemia and polycythemia vera, to mitigate the risks of thrombotic and hemorrhagic complications.
-
nih.gov
"Thrombocytosis agents" is an informal grouping rather than a distinct, standardized pharmacological class in major regulatory classifications such as the FDA Established Pharmacologic Class system
-
trialsearch.com
In clinical practice and reference databases, this term generally refers to platelet-lowering or cytoreductive agents used to reduce pathologically elevated platelet counts These therapies—most notably anagrelide, hydroxyurea, and interferon formulations—work by selectively inhibiting megakaryocyte maturation or exerting broader antineoplastic and antiproliferative effects in the bone marrow to curb excessive platelet production
-
mayoclinic.org
In clinical practice and reference databases, this term generally refers to platelet-lowering or cytoreductive agents used to reduce pathologically elevated platelet counts
-
trialsearch.com
These therapies—most notably anagrelide, hydroxyurea, and interferon formulations—work by selectively inhibiting megakaryocyte maturation or exerting broader antineoplastic and antiproliferative effects in the bone marrow to curb excessive platelet production
-
nih.gov
These therapies—most notably anagrelide, hydroxyurea, and interferon formulations—work by selectively inhibiting megakaryocyte maturation or exerting broader antineoplastic and antiproliferative effects in the bone marrow to curb excessive platelet production Their primary therapeutic role is in hematology for myeloproliferative neoplasms, most prominently essential thrombocythemia and polycythemia vera, to mitigate the risks of thrombotic and hemorrhagic complications
-
aabb.org
Their primary therapeutic role is in hematology for myeloproliferative neoplasms, most prominently essential thrombocythemia and polycythemia vera, to mitigate the risks of thrombotic and hemorrhagic complications
-
merckmanuals.com
Their primary therapeutic role is in hematology for myeloproliferative neoplasms, most prominently essential thrombocythemia and polycythemia vera, to mitigate the risks of thrombotic and hemorrhagic complications
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.